NASDAQ · SERVICES-MEDICAL LABORATORIES
BillionToOne, Inc. BLLN
3 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$305.1M
▲ 100.0% vs FY2024
EPS · FY25
$0.14
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
6.5%
Net margin · FY25
2.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 305.1M
Revenue, FY2025 · full 3-year series below
Revenue
Net income
2 cents of every revenue dollar became profit this year.
Per share
USD 0.14
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
6.5%
Return on equity, FY2025
ROE
Operating margin5.3%
Net margin2.4%
Return on assets1.6%
Each USD of equity produced 7 cents of profit this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD -3.1M
Share of profit0.0%
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 632.7M
total assets, end of FY2025
Total assetsUSD 632.7M
EquityUSD 480.1M
CashUSD 496.0M
Gross debtUSD 57.2M
Net debtUSD -438.7M
Current ratio11.69×
The company holds more cash than debt.
History
3 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
Revenue $B
0.3
0.2
0.1
Operating income $B
0.0
−0.0
−0.1
EBITDA $B
0.0
−0.0
−0.1
Income tax $B
0.0
0.0
0.0
Net income $B
0.0
−0.0
−0.1
EPS, diluted $
0.14
−4.12
−8.45
Dividend / sh $
·
·
·
Payout %
·
·
·
ROE %
6.5
·
·
Shares out B
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
10 of 10
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed